Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer

Endocrine-Related Cancer

Volumn 22, Issue 4, 2015, Pages 593-607

  Benesch, Matthew G K ^a   Ko, Yi M ^a   Tang, Xiaoyun ^a   Dewald, Jay ^a   Lopez Campistrous, Ana ^a   Zhao, Yuan Y ^b   Lai, Raymond ^b   Curtis, Jonathan M ^b   Brindley, David N ^a   McMullen, Todd P W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LYSOPHOSPHOLIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; ONO 8430506; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; AUTACOID; LYSOPHOSPHATIDIC ACID; PHOSPHODIESTERASE;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BENIGN TUMOR; CANCER CELL; CELL INFILTRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIFFERENTIAL DIAGNOSIS; EXPERIMENTAL MOUSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MITOSIS INDEX; MOUSE; NONHUMAN; PHENOTYPE; PRIMARY TUMOR; PROTEIN EXPRESSION; SCID MOUSE; SIGNAL TRANSDUCTION; THYROID CANCER; TUMOR GROWTH; TUMOR VOLUME; AGED; ANIMAL; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; THYROID GLAND; THYROID TUMOR;

ADULT; AGED; ANIMALS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, SCID; MIDDLE AGED; PHOSPHORIC DIESTER HYDROLASES; THYROID GLAND; THYROID NEOPLASMS;

EID: 84940101135     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0045     Document Type: Article

References (65)

1. Albers HM & Ovaa H 2012 Chemical evolution of autotaxin inhibitors. Chemical Reviews 112 2593-2603. (doi:10.1021/cr2003213)
2. Allavena P, Garlanda C, Borrello MG, Sica A & Mantovani A 2008 Pathways connecting inflammation and cancer. Current Opinion in Genetics & Development 18 3-10. (doi:10.1016/j.gde.2008.01.003)
3. Altman MK, Gopal V, Jia W, Yu S, Hall H, Mills GB, McGinnis AC, Bartlett MG, Jiang G, Madan D et al. 2010 Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Molecular Cancer 9 1476-4598. (doi:10.1186/1476-4598-9-140)
4. Ambesi-Impiombato FS, Parks LA & Coon HG 1980 Culture of hormonedependent functional epithelial cells from rat thyroids. PNAS 77 3455-3459. (doi:10.1073/pnas.77.6.3455)
5. Anderson RT, Linnehan JE, Tongbram V, Keating K & Wirth LJ 2013 Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid 23 392-407. (doi:10.1089/thy.2012.0520)
6. Azizi G, Keller JM, Lewis M, Piper K, Puett D, Rivenbark KM & Malchoff CD 2014 Association of Hashimoto's thyroiditis with thyroid cancer. Endocrine-Related Cancer 21 845-852. (doi:10.1530/ERC-14-0258)
7. Barbayianni E, Magrioti V, Moutevelis-Minakakis P & Kokotos G 2013 Autotaxin inhibitors: a patent review. Expert Opinion on Therapeutic Patents 23 1123-1132. (doi:10.1517/13543776.2013.796364)
8. Barbayianni E, Kaffe E, Aidinis V & Kokotos G 2015 Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer. Progress in Lipid Research 58 76-96. (doi:10.1016/j.plipres.2015.02.001)
9. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA & Fahey TJ III 2003 Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clinical Cancer Research 9 1792-1800.
10. Benesch MGK, Ko YM, McMullen TPW & Brindley DN 2014a Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions. FEBS Letters 588 2712-2727. (doi:10.1016/j.febslet.2014.02.009)
11. Benesch MGK, Tang X, Maeda T, Ohhata A, Zhao YY, Kok BPC, Dewald J, Hitt M, Curtis JM, McMullen TPW et al. 2014b Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB Journal 28 2655-2666. (doi:10.1096/fj.13-248641)
12. Benesch MGK, Zhao YY, Curtis JM, McMullen TPW & Brindley DN 2015 Regulation of autotaxin expression by lysophosphatidate and sphingosine 1-phosphate. Journal of Lipid Research 56 1134-1144. (doi:10.1194/jlr.M057661)
13. Bhave SR, Dadey DY, Karvas RM, Ferraro DJ, Kotipatruni RP, Jaboin JJ, Hallahan AN, Dewees TA, Linkous AG, Hallahan DE et al. 2013 Autotaxin inhibition with PF-8380 enhances the radiosensitivity of human and murine glioblastoma cell lines. Frontiers in Oncology 3 00236. (doi:10.3389/fonc.2013.00236)
14. Bozec A, Lassalle S, Hofman V, Ilie M, Santini J & Hofman P 2010 Thethyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential Current Medicinal Chemistry 17 3449-3461. (doi:10.2174/092986710792927804)
15. Brindley DN, Lin FT & Tigyi GJ 2013 Role of the autotaxinlysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochimica et Biophysica Acta 1831 74-85. (doi:10.1016/j.bbalip.2012.08.015)
16. Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Muller U, Murakami M, Radimerski T & Bentires-Alj M 2012 JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 22 796-811. (doi:10.1016/j.ccr.2012.10.023)
17. Chopra M, Riedel SS, Biehl M, Krieger S, von KrosigkV, Bauerlein CA, Brede C, Jordan Garrote AL, Kraus S, Schafer V et al. 2013 Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis. Carcinogenesis 34 1296-1303. (doi:10.1093/carcin/bgt038)
18. Chou WC, Chen JS, Hung YS, Hsu JT, Chen TC, Sun CF, Lu CH & Hwang TL 2014 Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors. Anticancer Research 34 5661-5669.
19. Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV et al. 2013 An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nature Medicine 19 1114-1123. (doi:10.1038/nm.3291)
20. Colotta F, Allavena P, Sica A, Garlanda C & Mantovani A 2009 Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30 1073-1081. (doi:10.1093/carcin/bgp127)
21. Cunha LL, Marcello MA, Nonogaki S, Morari EC, Soares FA, Vassallo J & Ward LS 2014a CD8C tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer. Clinical Endocrinology. (doi:10.1111/cen.12586)
22. Cunha LL, Marcello MA & Ward LS 2014b The role of the inflammatory microenvironment in thyroid carcinogenesis. Endocrine-Related Cancer 21 R85-R103. (doi:10.1530/ERC-13-0431)
23. Dvorak HF 1986 Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine 315 1650-1659. (doi:10.1056/NEJM198612253152606)
24. Ehlers M & Schott M 2014 Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked? Trends in endocrinology and metabolism 25 656-664. (doi:10.1016/j.tem.2014.09.001)
25. Euer N, Schwirzke M, Evtimova V, Burtscher H, Jarsch M, Tarin D & Weidle UH 2002 Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines. Anticancer Research 22 733-740.
26. Federico L, Pamuklar Z, Smyth SS & Morris AJ 2008 Therapeutic potential of autotaxin/lysophospholipase d inhibitors. Current Drug Targets 9 698-708. (doi:10.2174/138945008785132439)
27. Gaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR & Brindley DN 2009 Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Molecular Carcinogenesis 48 801-809. (doi:10.1002/mc.20524)
28. Germano G, Allavena P & Mantovani A 2008 Cytokines as a key component of cancer-related inflammation. Cytokine 43 374-379. (doi:10.1016/j.cyto.2008.07.014)
29. Grivennikov SI 2013 Inflammation and colorectal cancer: colitis-associated neoplasia. Seminars in Immunopathology 35 229-244. (doi:10.1007/s00281-012-0352-6)
30. Hanahan D & Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144 646-674. (doi:10.1016/j.cell.2011.02.013)
31. Hassan AM, Alm El-Din MA, Nagy H, Ghoneem N, El-Heniedy MA, Koteb N & El-Gohary S 2013 Significance of autotaxin activity and overexpression in comparison to soluble intercellular adhesion molecule in thyroid cancer. International Journal of Biological Markers 28 84-91. (doi:10.5301/JBM.2013.10780)
32. Hozumi H, Hokari R, Kurihara C, Narimatsu K, Sato H, Sato S, Ueda T, Higashiyama M, Okada Y, Watanabe C et al. 2013 Involvement of autotaxin/lysophospholipase D expression in intestinal vessels in aggravation of intestinal damage through lymphocyte migration. Laboratory Investigation 93 508-519. (doi:10.1038/labinvest.2013.45)
33. Hughes DT, Laird AM, Miller BS, Gauger PG & Doherty GM 2012 Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin. Annals of Surgical Oncology 19 2951-2957. (doi:10.1245/s10434-012-2380-9)
34. Jankowski M2011 Autotaxin: its role in biology of melanoma cells and as a pharmacological target. Enzyme Research 8 194857. (doi:10.4061/2011/194857)
35. Jonkers J & Moolenaar WH 2009 Mammary tumorigenesis through LPA receptor signaling. Cancer Cell 15 457-459. (doi:10.1016/j.ccr.2009.05. 003)
36. Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, Sigurdson AJ & Nikiforov YE 2014 The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. Journal of Clinical Endocrinology and Metabolism 99 E276-E285. (doi:10.1210/jc.2013-2503)
37. Kehlen A, Englert N, Seifert A, Klonisch T, Dralle H, Langner J & Hoang-Vu C 2004 Expression, regulation and function of autotaxin in thyroid carcinomas. Journal of Clinical Endocrinology 109 833-838. (doi:10.1002/ijc.20022)
38. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, Yamori T, Aoki J, Fujimaki T & Arai H 2006 Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. Journal of Biological Chemistry 281 17492-17500. (doi:10.1074/jbc.M601803200)
39. Li J, Lan T, Zhang C, Zeng C, Hou J, Yang Z, Zhang M, Liu J & Liu B 2015 Reciprocal activation between IL-6/STAT3 and NOX4/Akt signalings promotes proliferation and survival of non-small cell lung cancer cells. Oncotarget 6 1031-1048.
40. Mantovani A 2010 Molecular pathways linking inflammation and cancer. Current Molecular Medicine 10 369-373. (doi:10.2174/156652410791316968)
41. Marcello MA, Cunha LL, Batista FA & Ward LS 2014 Obesity and thyroid cancer. Endocrine-Related Cancer 21 T255-T271. (doi:10.1530/ERC-14-0070)
42. Murata J, Lee HY, Clair T, Krutzsch HC, Arestad AA, Sobel ME, Liotta LA & Stracke ML 1994 cDNA cloning of the human tumor motilitystimulating protein, autotaxin, reveals a homology with phosphodiesterases. Journal of Biological Chemistry 269 30479-30484.
43. Nakanaga K, Hama K & Aoki J 2010 Autotaxin - an LPA producing enzyme with diverse functions. Journal of Biochemistry 148 13-24. (doi:10.1093/jb/mvq052)
44. Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikolaidou-Katsaridou N, Zhao Z, Mersinias V, Armaka M, Xu Y, Masu M et al. 2012 Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. Journal of Experimental Medicine 209 925-933. (doi:10.1084/jem.20112012)
45. Oikonomou E & Pintzas A 2013 The TRAIL of oncogenes to apoptosis. BioFactors 39 343-354. (doi:10.1002/biof.1112)
46. Okudaira S, Yukiura H & Aoki J 2010 Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 92 698-706. (doi:10.1016/j.biochi.2010.04.015)
47. Pellegriti G, Frasca F, Regalbuto C, Squatrito S & Vigneri R 2013 Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. Journal of Cancer Epidemiology 2013 965212. (doi:10.1155/2013/965212)
48. Provatopoulou X, Georgiadou D, Sergentanis TN, Kalogera E, Spyridakis J, Gounaris A & Zografos GN 2014 Interleukins as markers of inflammation in malignant and benign thyroid disease. Inflammation Research 63 667-674. (doi:10.1007/s00011-014-0739-z)
49. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G & Bar-Sagi D 2012 Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21 836-847. (doi:10.1016/j.ccr.2012.04.024)
50. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM & Matrisian LM 2014 Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid. liver, and pancreas cancers in the United States. Cancer Research 74 2913-2921. (doi:10.1158/0008-5472.CAN-14-0155)
51. Saga H, Ohhata A, Hayashi A, Katoh M, Maeda T, Mizuno H, Takada Y, Komichi Y, Ota H, Matsumura N et al. 2014 A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension. PLoS ONE 9 e93230. (doi:10.1371/journal.pone.0093230)
52. Samadi N, Gaetano C, Goping IS & Brindley DN 2009 Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 28 1028-1039. (doi:10.1038/onc.2008.442)
53. Schafer M & Werner S 2008 Cancer as an overhealing wound: an old hypothesis revisited. Nature Reviews. Molecular Cell Biology 9 628-638. (doi:10.1038/nrm2455)
54. Schleicher SM, Thotala DK, Linkous AG, Hu R, Leahy KM, Yazlovitskaya EM & Hallahan DE 2011 Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS ONE 6 e22182. (doi:10.1371/journal.pone.0022182)
55. Seifert A, Klonisch T, Wulfaenger J, Haag F, Dralle H, Langner J, Hoang-Vu C & Kehlen A 2008 The cellular localization of autotaxin impacts on its biological functions in human thyroid carcinoma cells. Oncology Reports 19 1485-1491. (doi:10.3892/or.19.6.1485)
56. TafaniM, De Santis E, Coppola L, Perrone GA, Carnevale I, Russo A, Pucci B, Carpi A, Bizzarri M & Russo MA 2014 Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression. Biomedicine & Pharmacotherapy 68 1-5. (doi:10.1016/j.biopha.2013.10.013)
57. Tjomsland V, Bojmar L, Sandstrom P, Bratthall C, Messmer D, Spangeus A & Larsson M 2013 IL-1a expression in pancreatic ductal adenocarcinoma affects the tumor cell migration and is regulated by the p38MAPK signaling pathway. PLoS ONE 8 e70874. (doi:10.1371/journal.pone.0070874)
58. Turner MD, Nedjai B, Hurst T & Pennington DJ 2014 Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochimica et Biophysica Acta 1843 2563-2582. (doi:10.1016/j.bbamcr.2014.05.014)
59. Venkatraman G, Benesch MG, Tang X, Dewald J, McMullen TP & Brindley DN 2015 Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment. FASEB Journal 29 772-785. (doi:10.1096/fj.14-262659)
60. Wang K, Kim MK, Di Caro G, Wong J, Shalapour S, Wan J, Zhang W, Zhong Z, Sanchez-Lopez E, Wu LW et al. 2014 Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 41 1052-1063. (doi:10.1016/j.immuni.2014.11.009)
61. Ward LS 2014 Immune response in thyroid cancer: widening the boundaries. Scientifica 2014 125450. (doi:10.1155/2014/125450)
62. Wu JM, Xu Y, Skill NJ, Sheng H, Zhao Z, Yu M, Saxena R & Maluccio MA 2010 Autotaxin expression and its connection with the TNF-α-NF-κB axis in human hepatocellular carcinoma. Molecular Cancer 9 1476-4598. (doi:10.1186/1476-4598-9-71)
63. Xue Y, Lim S, Yang Y, Wang Z, Jensen LDE, Hedlund E-M, Andersson P, Sasahara M, Larsson O, Galter D et al. 2012 PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nature Medicine 18 100-110. (doi:10.1038/nm.2575)
64. Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J, Fells JI, Perygin D, Parrill AL, Tigyi G et al. 2009 Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Research 69 5441-5449. (doi:10.1158/0008-5472.CAN-09-0302)
65. Zhang J, Wang P, Dykstra M, Gelebart P, Williams D, Ingham R, Adewuyi EE, Lai R & McMullen T 2012 Platelet-derived growth factor receptor-a promotes lymphatic metastases in papillary thyroid cancer. Journal of Pathology 228 241-250. (doi:10.1002/path.4069)